Andere Sprachen DexCom, Inc.

Aktien

A0D9T1

US2521311074

DXCM

Medizinische Versorgung

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 06.02.2026			% 5 Tage	Veränd. 1. Jan.
69,97 ^USD	+0,11 %		-4,20 %	+5,42 %

06.02.	Tagebuch - US-Unternehmensgewinne in der kommenden Woche	RE
05.02.	Insulet bringt Omnipod® 5 und Omnipod Discover? im Nahen Osten auf den Markt, um die Diabetesversorgung zu revolutionieren	CI

Andere Sprachen

06.02.	Diary - U.S. earnings week ahead
05.02.	Insulet Launches Omnipod® 5 and Omnipod Discover? in the Middle East to Transform Diabetes Care
04.02.	Dexcom, Inc. to Roll Out an Advanced Ai-Enabled Enhancement to Stelo
04.02.	Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management
29.01.	HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
27.01.	Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.
27.01.	INVESTOR NOTICE: Kaskela Law Firm Announces Stockholder Investigation of DexCom, Inc. (NASDAQ: DXCM) and Encourages Long-Term Investors to Contact the Firm
23.01.	Valores destacados al cierre del mercado norteamericano
23.01.	Compañías que se deben tener muy en cuenta por técnico este lunes
15.01.	Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights
13.01.	Valores destacados al cierre del mercado norteamericano
12.01.	US Equity Markets Up Amid Rise in Precious Metals
12.01.	DexCom, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025 and Provides Earnings Guidance for the Fiscal Year 2026
12.01.	Dexcom Updates Fiscal 2025 Revenue Guidance; Sets 2026 Outlook
12.01.	(DXCM) DexCom Expects 2026 Total Revenue Range $5.16B - $5.25B, vs. FactSet Est of $5.23B
12.01.	Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
07.01.	Dexcom enters next era of continued innovation with Jake Leach as chief executive officer
07.01.	Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer
07.01.	US FDA to limit regulation of health and fitness wearables, commissioner says
29.12.	FDA says Dexcom issues correction for Dexcom G6 and G6 Pro software
26.12.	DexCom, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights - DXCM
24.12.	HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
23.12.	Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc.(DXCM) Shareholders
22.12.	DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - DXCM
20.12.	Important December 26, 2025 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Investors of Securities Fraud Class Action Lawsuit

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen MarketScreener Artikel MarketScreener Analysen Trading-Ideen

Filter

Schlagzeilen

DexCom: Unter Beschuss

Am 22. September 2025 um 17:46 Uhr